{"id":"W4389241514","doi":"10.1158/1535-7163.targ-23-b130","title":"Abstract B130: Phase 1 study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in patients with Human Epidermal Growth Factor 2 (HER2)-positive solid cancers","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada); McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Trastuzumab; Pharmacokinetics; Internal medicine; Population; Cancer; Pharmacology; Adverse effect; Antibody-drug conjugate; Oncology; Breast cancer; Antibody; Gastroenterology; Immunology; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001748064,0.0002817367,0.0005144762,0.0002131794,0.0001211413,0.00002033809,0.0001493443,0.00008663975,0.0002180268],"category_scores_gemma":[0.00001117824,0.0002210176,0.00006221861,0.0004641414,0.0001228852,0.0000785494,0.0001036412,0.0003908048,0.000005537077],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002068491,"about_ca_system_score_gemma":0.000197319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002828467,"about_ca_topic_score_gemma":0.0004317748,"domain_scores_codex":[0.9979197,0.0001251208,0.0004469549,0.0004279673,0.0005952405,0.0004850335],"domain_scores_gemma":[0.9991176,0.00007525141,0.0001570927,0.0002726458,0.0002190434,0.0001583876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01588282,0.005558936,0.8269795,0.0006856566,0.002473919,0.0006891883,0.008885251,0.00009082368,0.05815922,0.000076284,0.0002625273,0.08025588],"study_design_scores_gemma":[0.01454113,0.003745267,0.9594638,0.0001886901,0.0001312299,0.000002548279,0.000798358,0.0001855093,0.02028524,0.000026944,0.0003386326,0.0002926998],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996645,0.0002128174,0.00000976463,0.0007905882,0.00005537685,0.001418126,0.0005297321,0.00003315576,0.0003053877],"genre_scores_gemma":[0.9986715,0.0002181531,0.00005798249,0.0004428514,0.00003798737,0.00008511733,0.0003005252,0.00005334856,0.0001325056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1324843,"threshold_uncertainty_score":0.9012838,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04065824037030909,"score_gpt":0.3679402747168807,"score_spread":0.3272820343465717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}